遇见数据集

The clinical trials for safety and usefulness of chronic hepatitis therapeutics,agent 3-oxygelmillpropionic acid polymer for the advanced and recurrent colorectal cancer of having the existing chemotherapeutic refractory or intolerance.(Phase 1 test)

收藏
NIAID Data Ecosystem2026-03-09 收录
官方服务:

资源简介:

Interventions: The dose of Seroshion is 1 capsule (10mg) /time after each meal (3 times/day,30mg/day). The administration period is six months. Primary outcome(s): Safety Study Design: Single arm Non-randomized

创建时间:
2016-05-15
二维码
社区交流群
二维码
科研交流群
商业服务